MedTrace Logo

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

NCT00413036 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2017-03-01

Study results available
· View outcomes & findings →

Summary

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop

Conditions

  • Lymphoma, Non-Hodgkin's

Interventions

DRUG

lenalidomide

once daily oral capsule

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Lei Zhang, MD · Celgene Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413036 on ClinicalTrials.gov